FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products
Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…
AI Summary: The FDA is consolidating multiple safety reporting systems into a single public Adverse Event Monitoring System to centralize reports for drugs, biologics, vaccines, cosmetics and animal products. The move aims to improve transparency, reduce fragmented reporting, and streamline monitoring — a tidy solution if it works as promised.
Related Stories
FDA weighs easing access to compounded peptides for patients / 2 months
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
FDA launches individualized therapy framework for ultra-rare diseases / 4 months
FDA makes one pivotal trial the default for drug approvals / 4 months
FDA to review Moderna’s experimental flu vaccine after reversal / 4 months
FDA refuses to review Moderna mRNA flu vaccine application / 5 months
FDA rejects Atara cell therapy for Epstein–Barr virus complications / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Eli Lilly, Animal Health, Cybersecurity and look for the RSS link.
StackHealth Time Machine